http://www.inboxrobot.com/news/multiple-sclerosis-research-treatment Constantly updated news and information about a variety of topics. http://www.inboxrobot.com/news.php?fid=207352917 9 Jan 2009 18:30 GMT ... of MS. We are very grateful for this funding from a world leader in MS research." ... http://www.inboxrobot.com/news.php?fid=207306358 9 Jan 2009 13:46 GMT ... drug assets, the multiple sclerosis/Crohns disease drug Tysabri (natalizumab) and the investigational Alzheimers disease drug ... It would also get hold of Biogens MS drug Avonex (interferon beta-1a) and a share of revenues ... http://www.inboxrobot.com/news.php?fid=207305401 9 Jan 2009 13:44 GMT ... focussed on two issues: It is a potential takeover target; and (better than expected Tysabri patient numbers may be released. On the acquisition angle, Goodbody Stockbrokers consider that Elan ... http://www.inboxrobot.com/news.php?fid=207289353 9 Jan 2009 11:35 GMT ... the wrong patients. REMS can be fairly restrictive, like the one for Elan 's Tysabri, which involves enrollment in a program, or they can simply require the drug company ... http://www.inboxrobot.com/news.php?fid=207276951 9 Jan 2009 10:13 GMT ... Ireland." Goodbody analyst says acquisition speculation and/or Tysabri numbers driving current rally: "Elan has had ... new revenue drivers from Biogen Idec (including Avonex and a share of Rituxan), a large ... http://www.inboxrobot.com/news.php?fid=207275984 9 Jan 2009 10:11 GMT ... Ireland." Goodbody analyst says acquisition speculation and/or Tysabri numbers driving current rally: "Elan has had ... new revenue drivers from Biogen Idec (including Avonex and a share of Rituxan), a large ... http://www.inboxrobot.com/news.php?fid=207216501 9 Jan 2009 01:10 GMT Well, if you have been an incurable skeptic your entire life, then it might be the time for you to wonder why. At least, in ... http://www.inboxrobot.com/news.php?fid=207159911 8 Jan 2009 19:18 GMT ... and Warburtons Discount Butcher will supply the meat, so all profits can go to MS research. Mary-Faye has had MS for 13 years and has been camping in Mildura with ... http://www.inboxrobot.com/news.php?fid=207142182 8 Jan 2009 18:04 GMT ... Mississauga schools are joining thousands of students across the country in raising money for multiple sclerosis research and programs. The MS Read-A-Thon starts next Monday. Children will collect pledges for the ... http://www.inboxrobot.com/news.php?fid=207086045 8 Jan 2009 12:28 GMT ... Oral Multiple Sclerosis Drug More Effective, According to Trial Results Fingolimod, ... or Avonex. on average, the people receiving Avonex had 0.33 relapses per year while the ... means there could be an effective oral MS treatment available in 2010. This is great news ... http://www.inboxrobot.com/news.php?fid=207000410 8 Jan 2009 01:03 GMT ... Cause Of An Illness, So It Never Comes Back. Maybe you have experienced unsuccessful multiple sclerosis treatments in the past or maybe a painful breast cancer treatment diminished your spirits. Do ... http://www.inboxrobot.com/news.php?fid=206978496 7 Jan 2009 22:31 GMT ... has moved a long-acting version of its multiple sclerosis drug, Avonex, directly into trials designed to meet ... Elan Corp Plc ( ), also sells MS drug Tysabri, which was taken off the market ... have a much more bullish view on Tysabri than the Street does." "We've got a ... http://www.inboxrobot.com/news.php?fid=206969728 7 Jan 2009 21:50 GMT ... (Reuters) - Biogen Idec Inc ( ) has moved a long-acting version of its multiple sclerosis drug, Avonex, into trials designed to meet requirements for regulatory approval, the company's chief executive said ... http://www.inboxrobot.com/news.php?fid=206960554 7 Jan 2009 20:56 GMT ... 2 international offices in an attempt to combat slipping revenues on its benchmark drug, Tysabri. As long as these threats to the company's bottom line remain, analysts are unlikely ... http://www.inboxrobot.com/news.php?fid=206955943 7 Jan 2009 20:19 GMT ... 2 international offices in an attempt to combat slipping revenues on its benchmark drug, Tysabri. As long as these threats to the company's bottom line remain, analysts are unlikely ...